A CRISPR-Cas9 screen Reveals STEEP1 as a Key Host Dependency Factor for Epstein-Barr Virus Latent Membrane Protein 1 Trafficking and Signaling

This study identifies the ER-resident protein STEEP1 as a specific host dependency factor essential for Epstein-Barr virus LMP1 trafficking from the endoplasmic reticulum to signaling sites and subsequent activation of growth pathways, highlighting the LMP1/STEEP1 interaction as a novel therapeutic target.

The Gist

The Villain: A Sneaky Spy in the Cell

Imagine your body is a bustling city, and your immune system is the police force. The Epstein-Barr Virus (EBV) is a master spy that has been hiding in the city for decades (it infects nearly everyone). Usually, it stays quiet. But sometimes, it wakes up and starts a riot.

The virus's main weapon is a protein called LMP1. Think of LMP1 as a rogue alarm system.

• Normally, a cell only sounds an alarm when it needs help (like when a virus attacks).
• LMP1 is a "fake alarm" that is stuck in the "ON" position. It constantly screams, "We need to grow! We need to survive!"
• This constant screaming tricks the cell into growing uncontrollably, leading to cancers like lymphoma or nasopharyngeal carcinoma.

The Mystery: How Does the Alarm Get Turned On?

For the rogue alarm (LMP1) to work, it can't just sit in the factory where it's made (the Endoplasmic Reticulum, or ER). It has to be shipped out to the city streets (the cell membrane) and specific command centers inside the cell to start the chaos.

Scientists knew LMP1 was the bad guy, but they didn't know who was helping it get shipped out. They needed to find the "delivery drivers" or "logistics managers" that the virus hijacks to move its weapons around.

The Detective Work: A Genome-Wide "Wanted" Poster

To find these helpers, the scientists used a high-tech tool called CRISPR-Cas9. Imagine this as a giant "Wanted" poster for every single gene in a human cell (there are about 20,000 of them).

1. They took a population of cells and knocked out one gene at a time, like removing a specific worker from a factory line.
2. They then turned on the virus's rogue alarm (LMP1).
3. They asked: "If we remove this specific worker, does the alarm stop screaming?"

If the alarm stopped screaming, it meant that the missing worker was essential for the virus to do its job.

The Big Discovery: STEEP1, the "Traffic Cop"

Out of the 20,000 genes, one stood out: STEEP1.

• What is STEEP1? Think of it as a specialized traffic cop stationed at the factory gate (the ER).
• What does it do? Normally, STEEP1 helps a different protein (called STING) get out of the factory to fight real infections. But the virus has learned to trick STEEP1.
• The Hijack: The virus's rogue alarm (LMP1) grabs onto STEEP1's hand. STEEP1 thinks it's helping a good guy, so it opens the gate and lets LMP1 out of the factory.
• The Result: Once LMP1 is out, it starts its constant screaming, causing the cell to turn cancerous.

The Twist: It's a Specific Partnership

The scientists found something fascinating. STEEP1 is a traffic cop for many things, but it is only essential for this specific virus alarm.

• If you remove STEEP1, the virus alarm (LMP1) gets stuck in the factory and can't cause cancer.
• However, the cell's own normal alarms (like the CD40 receptor) still work fine without STEEP1.
• Analogy: It's like finding a specific key that only opens the back door of the bank vault. If you lose that key, the thieves can't get in, but the bank's front door and the teller's window still work perfectly. This means we could target this key without hurting the rest of the cell.

The Weakness: The "Handshake"

The scientists also figured out how the virus grabs the traffic cop.

• LMP1 has a long tail. The scientists found that the very tip of the tail (the N-terminal tail) is the "hand" that grabs STEEP1.
• If you cut off that tiny tip of the tail, the virus can't grab the traffic cop. The alarm gets stuck in the factory, and the cell is safe.

Why This Matters: A New Way to Fight Cancer

This discovery is a game-changer for two reasons:

1. A New Target: The virus itself (LMP1) is very hard to attack with drugs because it looks like our own proteins. But STEEP1 is a human protein. We can design drugs to block the "handshake" between the virus and STEEP1.
2. Safety: Since STEEP1 isn't needed for the cell's normal daily operations (only for this specific viral hijack), blocking it might kill the cancer cells without hurting healthy cells.

The Bottom Line

The virus is a master thief that needs a specific human accomplice (STEEP1) to smuggle its weapons out of the factory. The scientists found the accomplice and figured out exactly how the thief grabs their hand. Now, we have a blueprint for a new kind of medicine: a drug that breaks the handshake, leaving the virus stuck in the factory and the cancer cells unable to grow.

Technical Summary

1. Problem Statement

The Epstein-Barr virus (EBV) is a ubiquitous gamma-herpesvirus linked to various malignancies (e.g., nasopharyngeal carcinoma, Hodgkin lymphoma, post-transplant lymphoproliferative disease) and autoimmune conditions like multiple sclerosis. A central driver of EBV pathogenesis is the viral oncogene Latent Membrane Protein 1 (LMP1).

• Mechanism: LMP1 mimics the B-cell co-receptor CD40, constitutively activating growth and survival pathways (NF-κB, MAPK) in a ligand-independent manner.
• The Gap: LMP1 must traffic from the Endoplasmic Reticulum (ER) to the plasma membrane and intracellular signaling sites (lipid rafts, Golgi) to function. While the C-terminal signaling domains of LMP1 are well-studied, the specific host dependency factors that facilitate LMP1's egress from the ER and its subsequent trafficking to signaling sites remain largely undefined. Identifying these factors is crucial for understanding EBV pathogenesis and finding therapeutic targets, as LMP1 itself is considered "undruggable."

2. Methodology

The authors employed a systematic, genome-wide approach to identify host factors essential for LMP1 function.

• Cell Models:
  • Daudi and Akata Burkitt B cells: Engineered with Cas9 and conditional, doxycycline (Dox)-inducible LMP1 expression. These cells are not dependent on LMP1 for survival, allowing for the study of LMP1 function without immediate cell death.
  • Lymphoblastoid Cell Lines (LCLs): (GM12878, GM15892) which are strictly dependent on LMP1 for survival.
  • YCCEL1: EBV-positive gastric carcinoma cells (epithelial context) engineered for inducible LMP1.
• Genome-wide CRISPR-Cas9 Screen:
  • Library: Brunello human genome-wide sgRNA library.
  • Selection Strategy: Daudi cells were transduced with the library. LMP1 expression was induced via Dox.
  • Readout: Cells were stained for FAS (CD95), a known LMP1 target gene. The researchers sorted the bottom 5% of cells with the lowest plasma membrane FAS expression (indicating impaired LMP1 signaling) while maintaining GFP expression (to control for general cell health/transduction efficiency).
  • Analysis: sgRNA abundance in sorted vs. input populations was quantified via NGS. Hits were identified using the STARS algorithm.
• Validation & Mechanistic Studies:
  • Signaling Assays: Immunoblotting for non-canonical NF-κB (p100 to p52 processing), MAPK (p38 phosphorylation), and target genes (TRAF1, FAS).
  • Trafficking Analysis: Subcellular fractionation (Plasma Membrane vs. Cytosol), Confocal microscopy (co-localization with ER marker KDEL and Golgi marker GM130), and ImageStream flow cytometry.
  • Protein Interaction: Co-immunoprecipitation (Co-IP) using HA/FLAG tags to verify physical association between LMP1 and STEEP1.
  • Mutagenesis: Generation of LMP1 deletion mutants (N-terminal and C-terminal tails) to map the interaction interface.

3. Key Contributions

• Discovery of STEEP1: Identified STEEP1 (STING ER Exit Protein 1), an ER-resident protein previously known for facilitating the trafficking of the innate immune sensor STING, as a critical host factor for LMP1.
• Specificity: Demonstrated that STEEP1 is specific to LMP1 and not a general chaperone for all ER-transmembrane proteins, as it was not required for CD40 signaling or FAS trafficking in the absence of LMP1.
• Mechanistic Insight: Defined the molecular mechanism by which STEEP1 supports LMP1: it binds to the N-terminal cytoplasmic tail of LMP1 to facilitate ER egress and Golgi trafficking.
• Therapeutic Targeting: Proposed the LMP1/STEEP1 interaction as a novel, druggable therapeutic target to block EBV-driven oncogenesis and autoimmunity.

4. Key Results

• Screen Results:

  • The screen successfully recovered known LMP1 mediators (TRAF6, IKK complex subunits, NF-κB subunits).
  • STEEP1 emerged as a top hit (ranked #55, #77, #81, #144 among sgRNAs).
  • Cross-comparison with a prior CD40 screen showed STEEP1 was a hit for LMP1 but not for CD40, confirming specificity. STEEP1 depletion did not impair CD40-induced FAS expression or CD37 trafficking.

• Impact on Signaling:

  • Depletion of STEEP1 in Daudi, Akata, and LCLs strongly impaired LMP1-driven signaling.
  • Markers: Reduced p100-to-p52 processing (non-canonical NF-κB), reduced p38 phosphorylation (MAPK), and downregulation of target genes (FAS, TRAF1).
  • Proliferation: STEEP1 knockout caused rapid cessation of proliferation in LCLs (which rely on LMP1) but had a less severe effect on Burkitt cells (which are less dependent on LMP1 for survival).

• Trafficking Defects:

  • Subcellular Localization: In STEEP1-depleted cells, LMP1 failed to reach the plasma membrane.
  • ER Retention: Confocal microscopy and ImageStream analysis showed increased co-localization of LMP1 with the ER marker KDEL and decreased co-localization with the Golgi marker GM130.
  • This phenotype was observed in both B cells (Daudi, LCLs) and epithelial cells (YCCEL1).

• Physical Interaction & Domain Mapping:

  • Co-IP: STEEP1 physically associates with LMP1 in Daudi cells, FLAG-LMP1 LCLs, and reciprocal pulldowns in GM12878.
  • N-terminal Tail: Deletion of LMP1 residues 6–17 in the N-terminal cytoplasmic tail abolished the interaction with STEEP1.
  • C-terminal Tail: Deletions in the C-terminal tail (residues 231–386) did not affect STEEP1 binding.
  • Functional Consequence: The LMP1 Δ6–17 mutant failed to traffic to the Golgi/Plasma membrane and showed impaired signaling, phenocopying STEEP1 depletion.

5. Significance

• Novel Pathway: This study reveals a previously unknown host-virus interaction where EBV hijacks the STEEP1 machinery (normally used for STING innate immune signaling) to traffic its oncogene LMP1.
• Therapeutic Potential: Since LMP1 itself is difficult to target directly, disrupting the LMP1/STEEP1 interface offers a viable strategy to block EBV-driven malignancies (lymphomas, nasopharyngeal carcinoma) and potentially EBV-associated autoimmunity (Multiple Sclerosis).
• Selectivity: The finding that STEEP1 is dispensable for general ER-to-Golgi trafficking (e.g., CD40, VSV-G) but essential for LMP1 suggests that targeting this specific interaction could minimize off-target toxicity, as STEEP1 knockout is tolerated in most non-EBV-transformed cell lines (per DepMap data).
• Mechanistic Model: The paper proposes a model where the LMP1 N-terminal tail (residues 6–17) recruits STEEP1 to the ER membrane to induce membrane curvature and COPII-mediated vesicle formation, enabling LMP1 egress to signaling sites.

In conclusion, the authors successfully utilized a CRISPR screen to identify STEEP1 as a non-redundant host dependency factor for EBV LMP1, defining a specific molecular interface that could serve as a high-value target for antiviral and anti-cancer therapies.